Comment on

• Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.

  Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, Bleasdale P, Owen R, Higgins M, Kramer B; INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators. Dahl R, et al. Thorax. 2010 Jun;65(6):473-9. doi: 10.1136/thx.2009.125435. Thorax. 2010. PMID: 20522841 Clinical Trial.